keyword
MENU ▼
Read by QxMD icon Read
search

Vinflunine

keyword
https://www.readbyqxmd.com/read/27900539/seom-clinical-guideline-for-treatment-of-muscle-invasive-and-metastatic-urothelial-bladder-cancer-2016
#1
M Lázaro, E Gallardo, M Doménech, Á Pinto, A González Del Alba, J Puente, O Fernández, A Font, N Lainez, S Vázquez
The goal of this article is to provide recommendations for the diagnosis and treatment of muscle-invasive and metastatic bladder cancer. The diagnosis of muscle-invasive bladder cancer is made by pathologic evaluation after transurethral resection. Recently, a molecular classification has been proposed. Staging of muscle-invasive bladder cancer must be done by computed tomography scans of the chest, abdomen and pelvis and classified on the basis of UICC system. Radical cystectomy and lymph node dissection are the treatment of choice...
December 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27846935/-ccafu-french-national-guidelines-2016-2018-on-bladder-cancer
#2
M Rouprêt, Y Neuzillet, A Masson-Lecomte, P Colin, E Compérat, F Dubosq, N Houédé, S Larré, G Pignot, P Puech, M Roumiguié, E Xylinas, A Méjean
OBJECTIVE: The purpose of the guidelines national committee CCAFU on bladder cancer was to propose updated french guidelines for non-muscle invasive (NMIBC) and invasive (MIBC) bladder cancers. METHODS: A Medline search was achieved between 2013 and 2016, as regards diagnosis, options of treatment and follow-up of bladder cancer, to evaluate different references with levels of evidence. RESULTS: Diagnosis of NMIBC (Ta, T1, CIS) is based on a complete deep resection of the tumour...
November 2016: Progrès en Urologie
https://www.readbyqxmd.com/read/27812861/metastatic-bladder-cancer-second-line-treatment-and-recommendations-of-the-genitourinary-tumor-division-of-the-galician-oncologic-society-sog-gu
#3
REVIEW
Jorge García, Lucia Santomé, Urbano Anido, Ovidio Fernández-Calvo, Javier Afonso-Afonso, Martín Lázaro, Ana Medina, Sergio Vázquez Estévez
Once metastatic bladder cancer has progressed to first-line treatment, the number of therapeutic options is scarce. Among chemotherapeutic agents showing activity in phase II trials, including taxanes, vinflunine (VFL) is the only one shown to increase overall survival in a phase III trial. In addition to its efficacy, VFL is safe in special population groups. Despite this, the prognosis for these patients remains poor, and more effective therapies need to be developed. Agents acting on new therapeutic targets as well as biomarkers to aid matching patients to specific treatments are currently under evaluation...
December 2016: Current Oncology Reports
https://www.readbyqxmd.com/read/27771969/vinflunine-for-the-treatment-of-non-small-cell-lung-cancer
#4
C Genova, A Alama, S Coco, E Rijavec, M G Dal Bello, I Vanni, F Biello, G Barletta, G Rossi, F Grossi
Vinflunine belongs to the class of vinca alkaloids and acts by disrupting the microtubule dynamics during cell cycle; this agent is currently available for previously treated advanced transitional cell carcinoma in Europe. The aim of this invited review is to evaluate the potential role of vinflunine for the treatment of non-small cell lung cancer (NSCLC). Areas covered: The potential role of vinflunine in NSCLC is discussed on the basis of the available data, including full papers and meeting abstracts. Relevant preclinical studies describing the pharmacological properties of vinflunine are also included...
November 1, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27664126/epicure-a-european-epidemiological-study-of-patients-with-an-advanced-or-metastatic-urothelial-carcinoma-uc-having-progressed-to-a-platinum-based-chemotherapy
#5
N Houédé, G Locker, C Lucas, H Soto Parra, U Basso, D Spaeth, R Tambaro, L Basterretxea, F Morelli, C Theodore, L Lusuardi, N Lainez, A Guillot, G Tonini, J Bielle, X Garcia Del Muro
BACKGROUND: Platinum-based systemic chemotherapy is considered the backbone for management of advanced urothelial carcinomas. However there is a lack of real world data on the use of such chemotherapy regimens, on patient profiles and on management after treatment failure. METHODS: Fifty-one randomly selected physicians from 4 European countries registered 218 consecutive patients in progression or relapse following a first platinum-based chemotherapy. Patient characteristics, tumor history and treatment regimens, as well as the considerations of physicians on the management of urothelial carcinoma were recorded...
2016: BMC Cancer
https://www.readbyqxmd.com/read/27519420/metabolic-complete-response-with-vinflunine-as-second-line-therapy-in-a-kidney-transplanted-patient-with-advanced-urothelial-carcinoma-a-case-report
#6
Paola Bordi, Marcello Tiseo, Giorgio Baldari, Sebastiano Buti
BACKGROUND: Patients undergone kidney transplantation present higher risk of Urothelial Carcinoma (UC) development and represent a subgroup of special interest. To date, vinflunine is the only drug approved in Europe for the treatment of advanced UC after failure of platinum-based chemotherapy. However, to our knowledge, no data on the concomitant administration of vinflunine and immunosuppressive agents are available. CASE PRESENTATION: The patient, a 45 years old Caucasian male, presented poorly differentiated UC of the bladder recurred after initial cystectomy with abdominal lymphadenopathies evidenced by FDG-PET/CT...
2016: BMC Cancer
https://www.readbyqxmd.com/read/27484180/vinflunine-for-the-treatment-of-breast-cancer
#7
Carole Gourmelon, Héloïse Bourien, Paule Augereau, Anne Patsouris, Jean-Sébastien Frenel, Mario Campone
INTRODUCTION: Breast cancer is the most frequently diagnosed cancer and the highest cause of cancer mortality in females worldwide. The development of drugs improving overall survival in late-stage metastatic breast cancer remains a challenge. Vinflunine is the most recently developed drug in the vinca alkaloid class. Its arrival has been eagerly awaited for treatment of solid tumors, and in particular, for metastatic breast cancer. AREAS COVERED: The pharmacological features of vinflunine are described...
September 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27446429/vinflunine-treatment-in-patients-with-metastatic-urothelial-cancer-a-nordic-retrospective-multicenter-analysis
#8
Karin Holmsten, Line Dohn, Niels Viggo Jensen, Carl-Henrik Shah, Fredrik Jäderling, Helle Pappot, Anders Ullén
In 2009, vinflunine was introduced as a second-line treatment to be used after the failure of platinum therapy in patients with metastatic urothelial carcinoma (mUC). The present study investigated the administered vinflunine to patients with mUC in standard clinical practice with the aim of evaluating treatment patterns, response, survival parameters and side-effects. Data were collected retrospectively from the first 100 mUC patients treated with vinflunine at three Nordic cancer centers associated with the Nordic Urothelial Cancer Oncology Group...
August 2016: Oncology Letters
https://www.readbyqxmd.com/read/27353965/re-vinflunine-gemcitabine-versus-vinflunine-carboplatin-as-first-line-chemotherapy-in-cisplatin-unfit-patients-with-advanced-urothelial-carcinoma-results-of-an-international-randomized-phase-ii-trial-jasint1
#9
https://www.readbyqxmd.com/read/27306417/systemic-therapy-in-muscle-invasive-and-metastatic-bladder-cancer-current-trends-and-future-promises
#10
Jeanny B Aragon-Ching, Donald L Trump
Bladder urothelial cancers remain an important urologic cancer with limited treatment options in the locally advanced and metastatic setting. While neoadjuvant chemotherapy for locally advanced muscle-invasive cancers has shown overall survival benefit, clinical uptake in practice have lagged behind. Controversies surrounding adjuvant chemotherapy use are also ongoing. Systemic therapies for metastatic bladder cancer have largely used platinum-based therapies without effective standard second-line therapy options for those who fail, although vinflunine is approved in Europe as a second-line therapy based on a Phase III trial, and most recently, atezolizumab, a checkpoint inhibitor, was approved by the US FDA...
September 2016: Future Oncology
https://www.readbyqxmd.com/read/27262369/impact-of-prior-platinum-based-therapy-on-patients-receiving-salvage-systemic-treatment-for-advanced-urothelial-carcinoma
#11
G Sonpavde, G R Pond, G Di Lorenzo, C Buonerba, A Rozzi, G Lanzetta, A Necchi, P Giannatempo, D Raggi, K Matsumoto, T K Choueiri, S Mullane, G Niegisch, P Albers, J L Lee, H Kitamura, H Kume, J Bellmunt
BACKGROUND: Trials of salvage therapy for advanced urothelial carcinoma have required prior platinum-based therapy. This practice requires scrutiny because non-platinum-based first-line therapy may be offered to cisplatin-ineligible patients. PATIENTS AND METHODS: Data of patients receiving salvage systemic chemotherapy were collected. Data on prior first-line platinum exposure were required in addition to treatment-free interval, hemoglobin, Eastern Cooperative Oncology Group performance status, albumin, and liver metastasis status...
May 12, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27199753/from-clinical-trials-to-the-front-line-vinflunine-for-treatment-of-urothelial-cell-carcinoma-at-the-national-cancer-institute-of-naples
#12
Gaetano Facchini, Chiara Della Pepa, Carla Cavaliere, Sabrina C Cecere, Marilena Di Napoli, Carmine D'Aniello, Anna Crispo, Gelsomina Iovane, Piera Maiolino, Teresa Tramontano, Raffaele Piscitelli, Salvatore Pisconti, Maurizio Montella, Massimiliano Berretta, Domenico Sorrentino, Sisto Perdonà, Sandro Pignata
BACKGROUND: The efficacy of Vinflunine, after failure of platinum-based chemotherapy in patients with metastatic or recurrent Transitional Cell Cancer of the Urothelial Tract, TCCU, has been demonstrated in an international, randomized, phase III trial comparing Vinflunine plus Best Supportive Care, BSC, with BSC alone. On the basis of that study vinflunine has been approved by the European Medicine Association, EMA, for treatment of TCCU patients after failure of a platinum treatment...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/26975779/efficacy-and-safety-of-vinflunine-for-advanced-or-metastatic-urothelial-carcinoma-in-routine-practice-based-on-the-french-multi-centre-curve-study
#13
Jacques Médioni, Mario Di Palma, Aline Guillot, Dominique Spaeth, Christine Théodore
BACKGROUND: To retrospectively assess the efficacy and safety of Vinflunine (VFL) under routine conditions and identify overall survival (OS) prognostic factors. METHODS: Twenty centres participated in the retrospective study (minimum 4 patients undergoing VFL treatment for advanced/metastatic UC after platinum-based regimen progression. Primary endpoint was OS. Secondary endpoints: progression-free survival (PFS), radiological response rate (RR) RECIST criteria and toxicity (CTC NCI v3)...
2016: BMC Cancer
https://www.readbyqxmd.com/read/26857987/cytotoxic-chemotherapy-still-the-mainstay-of-clinical-practice-for-all-subtypes-metastatic-breast-cancer
#14
REVIEW
Chris Twelves, Maria Jove, Andrea Gombos, Ahmad Awada
Cytotoxic chemotherapy remains central to the treatment of all subtypes of metastatic breast cancer (MBC). We review evidence-based chemotherapy options for women with MBC after an anthracycline and a taxane including re-challenge with anthracycline or taxane, capecitabine, eribulin and ixabepilone as a single agent or combination with capecitabine (not approved in the EU); and the vinca alkaloid vinflunine as single agent or combined with either capecitabine/gemcitabine (also not approved EU or USA). Etirinotecan pegol, comprising irinotecan bound to polyethylene glycol by a biodegradable linker, is a new cytotoxic agent for patients with MBC that has achieved encouraging response rates in phase II studies; it has been further evaluated in the phase III BEACON trial...
April 2016: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/26844468/complete-response-and-fatigue-improvement-with-the-combined-use-of-cyclophosphamide-and-quercetin-in-a-patient-with-metastatic-bladder-cancer-a-case-report
#15
Giuseppe Di Lorenzo, Martina Pagliuca, Teresa Perillo, Aquilino Zarrella, Antonio Verde, Sabino De Placido, Carlo Buonerba
Bladder cancer is a major cause of cancer-related mortality, with an estimated 74,000 new cases and 16,000 deaths in the United States in 2015. In patients with metastatic disease, vinflunine and taxanes are the most widely used chemotherapy agents in the second-line setting after failure of platinum-based treatment. Cyclophosphamide has been used in combination with paclitaxel in urothelial carcinoma of the bladder, but there are no data about the effectiveness of cyclophosphamide administered as a single agent...
February 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/26780095/complete-and-durable-remission-of-human-epidermal-growth-factor-receptor-2-positive-metastatic-urothelial-carcinoma-following-third-line-treatment-with-trastuzumab-and-gemcitabine
#16
Felix Wezel, Philipp Erben, Timo Gaiser, Johannes Budjan, Jost von Hardenberg, Maurice Stephan Michel, Christian Bolenz
Urothelial carcinoma (UC) is one of the most common cancers and survival rates are low in metastatic disease with currently established first-line platinum-based chemotherapies. Unlike in many other cancers, no clinically established molecular targeted therapies exist for the treatment of this malignancy. Here we present a case of complete tumor remission following third-line treatment with trastuzumab and gemcitabine in a patient with human epidermal growth factor receptor 2 (HER2)-positive UC after progression under cisplatin and vinflunine chemotherapies...
January 19, 2016: Urologia Internationalis
https://www.readbyqxmd.com/read/26673352/vinflunine-gemcitabine-versus-vinflunine-carboplatin-as-first-line-chemotherapy-in-cisplatin-unfit-patients-with-advanced-urothelial-carcinoma-results-of-an-international-randomized-phase-ii-trial-jasint1
#17
M De Santis, P J Wiechno, J Bellmunt, C Lucas, W-C Su, L Albiges, C-C Lin, E Senkus-Konefka, A Flechon, L Mourey, A Necchi, W C Loidl, M M Retz, N Vaissière, S Culine
BACKGROUND: There is no standard first-line chemotherapy for advanced urothelial carcinoma (aUC) in cisplatin-ineligible (cisplatin-unfit) patients. The study assessed the efficacy and tolerability profile of two vinflunine-based cytotoxic regimens in this setting. PATIENTS AND METHODS: Patients with aUC a creatinine clearance (CrCl) of <60 but ≥30 ml/min, performance status 0 or 1 and no prior chemotherapy for advanced disease were randomized (1 : 1). They received vinflunine 250 or 280 mg/m(2) (based on baseline CrCl) on day 1, plus either gemcitabine [750 mg/m(2) escalated to 1000 mg/m(2) in cycle 2 if no toxicity grade (G) ≥2 on days 1 and 8 (VG) or plus carboplatin area under the curve 4...
March 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/26552764/second-line-chemotherapy-for-metastatic-urothelial-carcinoma-importance-of-lymph-node-only-metastasis-as-a-prognostic-factor-and-construction-of-a-prognostic-model
#18
Samer Salah, Jae-Lyun Lee, Antonio Rozzi, Hiroshi Kitamura, Kazumasa Matsumoto, Sandy Srinivas, Rafael Morales-Barrera, Joan Carles, Rami Al-Wardat, Kamal Al-Rabi, Mohammad Maakoseh
BACKGROUND: A prognostic model for patients with metastatic urothelial carcinoma (UC) progressing after platinum-based therapy was constructed from data from the phase III vinflunine trial. However, prognostic information for patients treated with other regimens is limited. MATERIALS AND METHODS: We pooled individual patient data from 7 second-line studies and analyzed the influence of factors of interest on overall survival (OS) through univariate and multivariate analysis...
June 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/26532623/influence-of-the-method-of-analysis-on-estimates-of-qaly-treatment-difference-phase-iii-trial-of-vinflunine-versus-best-supportive-care-in-patients-with-tccu
#19
G Berdeaux, N Roskell, M Hemstock
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/26532494/pharmacoeconomic-analysis-of-urothelial-transitional-cell-cancer-treatment-with-vinflunine-in-patients-resistant-to-the-platinum-based-treatment-regimes
#20
R Yagudina, A Kulikov, Y Rybchenko
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
31934
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"